CERC-006 is targeted towards complex Lymphatic Malformations (LM). Lymphatic Malformation patients often have activating mutations along the PI3K/AKT/mTOR pathway and sirolimus is an mTORC1 inhibitor that has demonstrated clinical utility in LM. CERC-006 has the potential to improve upon both the safety and efficacy of mTOR inhibition in LM. Currently the main therapeutic options for treating a lymphatic malformation are percutaneous drainage, surgery, sclerotherapy, laser therapy, radiofrequency ablation, or medical therapy. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-006 in LM patients in late 2020.